Monoclonal Antibody Therapy in Dyslipidemia

Primary Indications for PCSK9 Inhibitors

The American Heart Association recommends PCSK9 inhibitor monoclonal antibodies for patients with familial hypercholesterolemia, established atherosclerotic cardiovascular disease on maximally tolerated statin therapy who cannot achieve >50% LDL-C reduction, or in statin-intolerant patients at high cardiovascular risk, as these agents reduce LDL-C by 50-65% and significantly decrease cardiovascular events and mortality 1, 2, 3.
PCSK9 monoclonal antibodies enable substantial proportions of heterozygous familial hypercholesterolemia patients to achieve LDL-C <1.8 mmol/L (<70 mg/dL) for the first time, with efficacy appearing similar across most patient subgroups 1, 2.
In homozygous familial hypercholesterolemia patients on maximal lipid-lowering therapy, evolocumab 420 mg every 4 weeks reduces LDL-C by approximately 30%, with efficacy related to residual LDL receptor activity 2, 4.

PCSK9 monoclonal antibodies reduce LDL-C by 50-65% across patient populations 1, 4, 5.
On maximal statin therapy, mean LDL-C levels of approximately 0.9 mmol/L (35 mg/dL) are achievable, with many patients achieving LDL-C <0.64 mmol/L (25 mg/dL) 1, 2, 4.
Both agents reduce lipoprotein(a) by up to 25% 1, 2, 4, 5.

Meta-analysis of phase 2 and 3 trials demonstrated reduced total mortality with alirocumab and evolocumab in trials ranging from 12 to 78 weeks 1, 2, 5.
Preliminary data suggest PCSK9 monoclonal antibodies reduce cardiovascular events over 1 to 1.5 years 1, 2, 5.

Both evolocumab and alirocumab appear well tolerated in trials up to 78 weeks in duration 1, 2, 4, 5.
Injection site reactions are relatively infrequent and mild 1, 2, 5.
Myalgia was slightly more frequent with alirocumab compared to placebo 1, 2, 5.

Maximize statin dose to achieve >50% LDL-C reduction in high-risk patients before adding non-statin agents 7.
Patients with familial hypercholesterolemia (heterozygous or homozygous) are candidates for PCSK9 inhibitors 1, 2, 6.
High-risk patients with established atherosclerotic cardiovascular disease unable to tolerate high-intensity statin therapy are candidates for PCSK9 inhibitors 1, 2, 6.
Inclisiran is an alternative for patients preferring less frequent administration (every 6 months after loading doses), with placebo-corrected LDL-C reduction of 49.9-52.3% 3.